The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Characterization of Tumor-associated Chk2 Mutations
Open accessAbstract
The integrity of the DNA damage response pathway is essential for prevention of neoplastic transformation. Several proteins involved in this pathway including p53, BRCA1, and ATM are frequently mutated in human cancer. Checkpoint kinase 2 (Chk2) is a DNA damage-activated protein kinase that lies downstream of ATM in this pathway. Recently, heterozygous germline mutations in Chk2 have been identified in a subset of patients with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype, suggesting that Chk2 is a tumor suppressor gene. In this study, we have reported the biochemical characterization of the four tumor-associated Chk2 mutants. Two of the reported Chk2 mutations identified in Li-Fraumeni syndrome result in loss of Chk2 kinase activity. Whereas one mutation within the Chk2 forkhead homology-associated (FHA) domain, R145W, retains some basal kinase activity, this mutant cannot be phosphorylated at an ATM-dependent phosphorylation site (Thr-68) and cannot be activated following gamma radiation. Wild-type Chk2 exists mainly in a protein complex of M(r) approximately 200,000 whereas the R145W mutant forms a larger, presumably inactive complex in the cell. The other FHA domain mutant, I157T, behaves as wild-type Chk2 in all the assays used here. Because the FHA domain is involved in protein-protein interactions, this mutation may affect associations of Chk2 with other proteins. Additionally, we have shown that Chk2 can also be inactivated by down-regulation of its expression in cancer cells. Thus, Chk2 may be inactivated by multiple mechanisms in the cell.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Cited by
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage.
Lukas, C., Falck, J., Bartkova, J., Bartek, J., & Lukas, J. (2003) · Nature Cell Biology · doi:10.1038/ncb945 · Cited by 474
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455
Durocher, D., & Jackson, S. P. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03294-x · Cited by 428
Chk2 kinase — a busy messenger
Bartek, J., Falck, J., & Lukas, J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35103059 · Cited by 403
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage
Bobrovnikova-Marjon, E., Grigoriadou, C., Pytel, D., Zhang, F., Ye, J., Koumenis, C., Cavener, D., & Diehl, J. A. (2010) · Oncogene · doi:10.1038/onc.2010.153 · Cited by 300
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
Zhang, B., Beeghly-Fadiel, A., Long, J., & Zheng, W. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70076-6 · Cited by 272
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response
Ahn, J., Urist, M., & Prives, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213185200 · Cited by 99
Concomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91
Mutation analysis of the CHK2gene in families with hereditary breast cancer
Allinen, M., Huusko, P., Mäntyniemi, S., Launonen, V, & Winqvist, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1858 · Cited by 85
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
Ingvarsson, S., Sigbjornsdottir, B. I., Huiping, C., Hafsteinsdottir, S. H., Ragnarsson, G., Barkardottir, R. B., Arason, A., Egilsson, V., & Bergthorsson, J. T. (2002) · Breast Cancer Research · doi:10.1186/bcr435 · Cited by 63
Metadata
- Authors
- Wu, X., Webster, S. R., & Chen, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 276
- Issue
- 4
- Pages
- 2971-2974
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2038612913
- Cited by
- 175
- References
- 2
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.